New combo shows promise for rare cancers

NCT ID NCT02406781

Completed Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of two drugs—pembrolizumab (an immunotherapy) and cyclophosphamide (a chemotherapy)—in 129 people with advanced sarcomas that had spread or could not be removed by surgery. The goal was to see if the combination could shrink tumors or stop them from growing for at least 6 months. The trial included different types of sarcoma to see which might benefit most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (MK3475) and cyclophosphamide
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced sarcomas that are hard to treat.
What could go wrong: This is a phase 2 trial, so results are preliminary. The combination may not work for all sarcoma types and could cause side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor leiomyosarcoma osteosarcoma sarcoma soft tissue sarcoma undifferentiated pleomorphic sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69373, France
Centre Oscar Lambret

Lille, 59020, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut Curie

Paris, 75005, France
Institut Gustave Roussy

Villejuif, 94800, France
Institut Paoli Calmettes

Marseille, 13273, France
Institut de Cancérologie de l'Ouest

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.